Trulieve Becomes First U.S. Cannabis Company to Uplist to NYSE
Event summary
- Trulieve's subordinate voting shares approved for NYSE listing under ticker 'TRLV', effective June 10, 2026.
- Company completed corporate restructuring post-medical marijuana rescheduling to Schedule III in April 2026.
- Trulieve now operates 206 medical marijuana dispensaries with 3.5 million square feet of DEA-registered production capacity.
- Shares will delist from CSE and OTCQX after June 9, 2026 market close.
The big picture
Trulieve's NYSE uplist marks a pivotal moment for the cannabis industry, validating the sector's maturation following federal regulatory shifts. The move comes after President Trump's executive order and subsequent Schedule III reclassification, creating a clear pathway for DEA registration. This structural shift positions Trulieve to attract deeper institutional capital while setting a precedent for other vertically integrated cannabis operators.
What we're watching
- Regulatory Tailwinds
- How the Schedule III reclassification will accelerate other cannabis operators' NYSE ambitions.
- Market Expansion
- Whether Trulieve can sustain its growth trajectory through Georgia and Texas expansions.
- Investor Dynamics
- The pace at which institutional investors will allocate to cannabis stocks post-NYSE listing.